您的当前位置：首页 > 자동차 > Samsung Bioepis launches Soliris biosimilar in Europe 正文
时间：2023-12-02 20:59:26 来源：网络整理 编辑：자동차
Samsung Bioepis, a biosimilar developer under Samsung Group, said Thursday that the company has comp
Samsung Bioepis, a biosimilar developer under Samsung Group, said Thursday that the company has completed the launches of its hematology biosimilar Epysqli, a biosimilar close to Soliris, in three European countries, hoping to gain ground in the rare blood disease biosimilar market.
According to Samsung Bioepis, the company introduced Epysqli in Germany in July, and the biosimilar made its debut in Italy and Spain last month.
Samsung Bioepis is also preparing for Epysqli’s launch in France and the Netherlands within the year, the company said, adding that it is not planning on launching the biosimilar in other European countries beyond that.
Epysqli, a biosimilar close to Soliris (eculizumab), is a treatment for patients with paroxysmal nocturnal hemoglobinuria, a rare disease where red blood cells prematurely break apart.
PNH is a debilitating and often fatal disease, but can be treated with medication. However, the price of Soliris is around $500,000 per patient, per year, depending on a patient's weight. This price limits the treatment's accessibility and availability.
Soliris was originally developed by US-based Alexion Pharmaceuticals. But the rights to Soliris are currently owned by AsztraZeneca, which completed the acquisition of Alexion Pharmaceuticals in 2021.
“Samsung Bioepis is pleased that the company can increase the availability of the medication through its launches in Europe. The company will continue its efforts and contribute to unmet medical needs,” Samsung Bioepis said.
Samsung Bioepis’ Epysqli received marketing authorization from the European Commission in May, based on its phase 3 clinical trial conducted in eight countries between August 2019 and October 2021.
Adding Epysqli to its portfolio, Samsung Bioepis currently has seven biosimilars approved for use in Europe, including Benepali, an anti-inflammatory biosimilar close to Enbrel, and Imraldi, a biosimilar close to Humira.
Volvo EX30 debuts in Korea2023-12-02 20:39
정부, GP 복원 계획…김태효 "北 무장에 가만히 있으면 안된다"2023-12-02 20:28
Violinist Yoo Da2023-12-02 20:18
YouTuber suspected of livestreaming after taking drugs2023-12-02 20:17
Seoul shares start lower ahead of key rate decision2023-12-02 19:48
Transgender blind spot in hospitalization: NHRCK2023-12-02 19:28
'Do not open plane doors' warning mandated for planes in flight2023-12-02 19:06
Hanwha Ocean developing submarine stealth technology2023-12-02 18:46
Hanwha Ocean developing submarine stealth technology2023-12-02 18:45
정부, GP 복원 계획…김태효 "北 무장에 가만히 있으면 안된다"2023-12-02 18:20
Violinist Yoo Da2023-12-02 20:39
Cheong Wa Dae to open for winter night stroll event2023-12-02 20:23
Daily Sports Hankook hopes to help stengthen Korea2023-12-02 20:10
YouTuber suspected of livestreaming after taking drugs2023-12-02 20:06
Seoul shares start lower ahead of key rate decision2023-12-02 19:19
LS Materials to tap deeper into EV, green energy markets2023-12-02 18:58
Korea to showcase advanced climate technologies at COP28 Dubai2023-12-02 18:50
Daily Sports Hankook hopes to help stengthen Korea2023-12-02 18:43
Cheong Wa Dae to open for winter night stroll event2023-12-02 18:27